MediWound Launches $30 Million Registered Direct Offering; Stock Falls More Than 7%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 29 2025
0mins
Source: SeekingAlpha
Securities Purchase Agreement: MediWound has entered into a definitive agreement to sell 1.73 million ordinary shares at $17.30 each, expecting to close the offering around September 30, 2025.
Use of Proceeds: The company anticipates gross proceeds of approximately $30 million, which will be used to support EscharEx’s pre-commercial activities, enhance manufacturing capabilities, and for general corporate purposes.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on MDWD
Wall Street analysts forecast MDWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDWD is 30.00 USD with a low forecast of 25.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.420
Low
25.00
Averages
30.00
High
36.00
Current: 18.420
Low
25.00
Averages
30.00
High
36.00
About MDWD
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MediWound Reports NexoBrid Reduces Traumatic Tattoo Risk by 92.5%
- Clinical Data Release: MediWound's new clinical data published in the Journal of Burn Care & Research shows that NexoBrid® effectively prevents traumatic tattoos by significantly reducing embedded particles within 24 hours, achieving over a 90% reduction in pigmented wound area, which opens new possibilities for acute trauma treatment.
- Significant Treatment Effects: In a study involving 15 patients, the application of NexoBrid® reduced the pigmented wound area from 37.5% to 2.1%, with an average of 96% visible pigment removal in friction injuries and 84% in blast injuries, demonstrating its potential in managing complex trauma cases.
- High Safety Profile: The treatment process with NexoBrid® was performed at the bedside, well-tolerated by patients, and no treatment-related adverse events were reported during the early post-procedure period, establishing a solid foundation for its clinical application.
- Future Research Directions: Investigators call for larger controlled studies to confirm the long-term cosmetic effects of NexoBrid® and to explore its combined applications in complex trauma, further advancing the clinical use of this therapy.
Continue Reading
MediWound Reports NexoBrid's 92.5% Effectiveness in Preventing Traumatic Tattoos
- Clinical Data Release: MediWound's newly published prospective clinical data demonstrates that NexoBrid effectively prevents traumatic tattoos, with pigmented wound area decreasing from 37.5% to 2.1%, achieving a remarkable 92.5% reduction, significantly enhancing trauma management outcomes.
- Innovative Treatment Method: In a study involving 15 patients, NexoBrid was applied within 24 hours post-injury, successfully removing 96% of visible pigments, indicating its high efficacy in addressing friction and blast injuries, which could potentially transform current trauma care standards.
- Research Context: Conducted at Sheba National Burn Center, this study is the first to evaluate NexoBrid's application in preventing traumatic tattoos, highlighting its selective enzymatic action on damaged skin layers, which holds significant clinical implications.
- Future Research Directions: Despite the small sample size and short follow-up, the investigators call for larger controlled studies to confirm NexoBrid's impact on long-term cosmetic outcomes and to further explore its potential in complex trauma applications.
Continue Reading